Pedro Barata, MD, MSc, FACP
Pedro Barata, MD, MSc is a medical oncologist at University Hospitals Seidman Cancer Center and an associate professor of medicine at Case Western Reserve University School of Medicine.
Articles
Challenges, Unmet Needs, and the Future of Advanced Urothelial Carcinoma Management
June 21st 2024A key opinion leader addresses the persistent challenges and unmet needs in the management of advanced urothelial carcinoma, while offering their insight into the future direction and potential advancements within this rapidly evolving field of oncology.
Managing a Novel Therapeutic Option for mUC Treatment
June 21st 2024A leading medical authority shares their hands-on experience with sacituzumab govitecan, focusing on the primary toxicity concerns, such as diarrhea and neutropenia, and outlining effective management strategies to mitigate these adverse effects and optimize patient care.
Navigating Later-Line Therapies for Progressive Urothelial Cancer
June 21st 2024A key opinion leader delves into the intricacies of second-line and third-line treatment sequencing for patients with progressive disease, addressing the appropriate timing for repeat testing and elaborating on the critical factors that inform their personalized treatment approach.
Navigating First-Line Treatment Choices for Metastatic Urothelial Carcinoma
June 21st 2024A medical professional outlines their preferred first-line treatment strategy for managing patients diagnosed with metastatic urothelial carcinoma, providing valuable insights into their clinical decision-making process.
Expert Insights: Biomarker Evaluation and Timing in Management of Patients with mUC
June 21st 2024A leading expert in the field shares their insights on the specific biomarkers they evaluate, such as Trop2, FGFR, and PD-L1, and the optimal timing for conducting these tests based on their clinical experience and patient management strategies.
Examining Molecular Testing in Metastatic Urothelial Cancer: Present and Future
June 21st 2024A key opinion leader offers a comprehensive overview of the present landscape of molecular testing in metastatic urothelial cancer, elaborating on how advancements in molecular testing have shaped his clinical practice and expressing optimism for their future incorporation into the National Comprehensive Cancer Network (NCCN) guidelines.
Metastatic Urothelial Carcinoma: Optimizing Care Through Multidisciplinary Teamwork
June 21st 2024A urology expert elucidates the collaborative relationship between medical oncology and urology in terms of diagnostic testing, treatment strategies, and patient referrals, while underscoring the crucial role of a multidisciplinary approach in maximizing positive patient outcomes.
